Granted Orphan Designation from the European Medicines Agency for Iomab-B
· Orphan designation is expected to provide increased communication and guidance from regulators and 10-year market exclusivity should marketing authorization be obtained
· Orphan designation for Iomab-B follows SME (small or medium-sized enterprise) status, which was granted in August 2016
· Iomab-B now has orphan designation in the US and EU
NEW YORK - October 18, 2016 (Investorideas.com Newswire) Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company’s lead asset, Iomab-B, has been granted orphan designation in the European Union (EU) by the European Medicines Agency (EMA).
- Published: 19 October 2016
- Written by Investor Ideas